Auxilium’s Dupuytren's treatment gets FDA priority
Auxilium Pharmaceuticals, Inc. today said the U.S. Food and Drug Administration granted priority review status to its biologics license application for Xiaflex to treat Dupuytren's contracture.
Auxilium Pharmaceuticals, Inc. today said the U.S. Food and Drug Administration granted priority review status to its biologics license application for Xiaflex to treat Dupuytren's contracture.
The FDA is expected to take action on the application by Aug. 28.
Dupuytren's contracture is a disease that causes collagen to build up in hands and impairs patients' ability to straighten their fingers.
The Malvern company said Xiaflex breaks down excess collagen. - Miriam Hill
Matt Sedensky, Associated Press
Stan Choe, Associated Press
Paul Wiseman, Associated Press
Shannon Osaka, Washington Post
Cecilia Kang and Sophia June, New York Times
David McHugh and Paul Wiseman, Associated Press
Review
Andrew Ackerman, Bloomberg
Rebecca Robbins, New York Times
Julia Carpenter, Washington Post
Dear Abby, Inquirer wire services
























